Renovaro/RENB

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Renovaro

Renovaro Inc., formerly Renovaro BioSciences Inc., is a biotechnology company. The Company is engaged in the research and development of pharmaceutical and biological products for the treatment of cancer, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. The Company has a single product candidate as a potential cure for HIV, RENB-HV01, adding two additional pipeline candidates for HIV, RENB-HV12 and RENB-HV21, a pipeline for HBV, RENB-HB01, and with a significant into cancer immune therapies to address high unmet needs from difficult-to-treat solid tumors, RENB-DC11. RENB-HV-01 is a HIV autologous transplant with genetically modified cells. RENB-HV12 is a HIV therapeutic vaccine for potential long-term remission/cure. RENB-HV-21, a treatment for HIV with allogenic Natural Killer (NK) and Gamma Delta T-Cells (GDT). RENB-HB-01 is an HBV gene therapy candidate.

Ticker

RENB

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Mark Dybul

Employees

11

Headquarters

Los angeles, United States

Renovaro Metrics

BasicAdvanced
$220M
Market cap
-
P/E ratio
-$0.77
EPS
0.44
Beta
-
Dividend rate
$220M
0.43768
$5.25
$0.39
441K
0.058
4.223
-24.38%
-37.06%
-45.95%
-41.75%
1.303
61.73%

Renovaro Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$0
NaN%
Net income
-$17M
277.78%
Profit margin
0.00%
NaN%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Renovaro stock?

Renovaro (RENB) has a market cap of $220M as of June 17, 2024.

What is the P/E ratio for Renovaro stock?

The price to earnings (P/E) ratio for Renovaro (RENB) stock is 0 as of June 17, 2024.

Does Renovaro stock pay dividends?

No, Renovaro (RENB) stock does not pay dividends to its shareholders as of June 17, 2024.

When is the next Renovaro dividend payment date?

Renovaro (RENB) stock does not pay dividends to its shareholders.

What is the beta indicator for Renovaro?

Renovaro (RENB) has a beta rating of 0.44. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Renovaro stock price target?

The target price for Renovaro (RENB) stock is $, which is NaN% below the current price of $. This is an average based on projections from analyst, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Renovaro stock

Buy or sell Renovaro stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing